Latest news with #KwikPen
Time of India
2 hours ago
- Business
- Time of India
Eli Lilly to roll out diabetes medicine in prefilled pen
Eli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The KwikPen offers a convenient, once-weekly administration. It contains four fixed doses. This launch intensifies competition with Novo Nordisk's Wegovy. Mounjaro's dual mechanism may offer superior efficacy. The availability of all six dosage options will support personalized treatment. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads US pharmaceutical major Eli Lilly on Thursday announced its plan to launch blockbuster diabetes drug tirzepatide ) in KwikPen , a prefilled pen designed for once-a-week administration for single patients in the Indian market, two days after its rival Danish drug maker Novo Nordisk launched the weight loss drug Wegovy as a weekly injection in the country, intensifying competition in the booming obesity Lilly said it received the approval of the Indian drug regulatory authority but did not comment on the launch timeline. The expected price of the pen device was also not disclosed. Once launched, the company said each pen will deliver four fixed doses of 0.6 ml and has been approved in six dose strengths including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 launched earlier this week, is expected to be in the pharmacies by the end of this month. The delivery device will contain four doses of 0.25 mg, 0.5 mg and 1 mg priced at '17,345 a month. This translates into a weekly cost of '4,366. The 1.7 mg dose will be priced at '24,280 per month, and 2.4 mg dose will be priced at '26, Misra, chairman of Fortis C-DOC, Centre of Excellence for diabetes, metabolic diseases and endocrinology said Mounjaro's dual mechanism may offer superior efficacy, however "wider adoption" will depend on the "price" of the Tucker, president and general manager of Eli Lilly India, said the approval of Mounjaro KwikPen marks a step forward in the care of people living with type 2 diabetes and obesity, offering a convenient way for patients to take their medication. Mounjaro reduces body weight and decreases fat mass by regulating appetite."With this approval, all six dosage options for Mounjaro will soon be available in India, supporting a more personalised approach to treatment and allowing healthcare professionals to tailor care based on individual patient needs and clinical goals," he is the first and only dual GIP (glucose- dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and chronic weight management in adults with obesity or overweight, with one weight-related comorbidity.
The Print
3 hours ago
- Health
- The Print
In battle for Indian anti-obesity market, Eli Lilly's pre-filled pen on one side, Novo Nordisk's on other
The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorisation for Mounjaro in the KwikPen presentation, Eli Lilly said in a statement Thursday, adding that the approval marks an important step in advancing care for people living with type 2 diabetes and obesity in India. Mounjaro by US-based Eli Lilly & Company, which has tirzepatide as its active pharmaceutical ingredient (API), was launched in India on 20 March this year in vial format, which meant it was more cumbersome to administer. New Delhi: Eli Lilly India, makers of the obesity drug Mounjaro, said Thursday that they have received approvals from the Indian regulator for their pre-filled pen, a day after competitor Novo Nordisk's global mega-selling drug for obesity, Wegovy, hit the Indian markets. The pens offer a convenient way for patients to take their medication. First developed as a treatment for type 2 diabetes in lower doses, both Mounjaro and Wegovy are weekly injections intended to dramatically reduce weight in obese patients. They have emerged as global sensations in the pharmaceutical market world over, with their sales reaching multi-billion-dollar figures. These drugs have also been fighting to dominate the obesity management space in many developed countries. They are now aiming to capture a share of the market in India, where obesity is growing rapidly, driven by changing dietary and lifestyle patterns. India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore, and is projected to grow nearly eightfold to Rs 25,000 crore by 2030, according to market estimates. A 2023 survey by the Indian Council of Medical Research (ICMR) and Madras Diabetes Research Foundation (MDRF) had shown that 25.4 crore Indians, or 28.6 percent, of the population had generalised obesity. Obesity, now recognised as a chronic, relapsing disease, is a major risk factor for diabetes and is linked to over 200 health complications, including hypertension, dyslipidemia or high blood cholesterol, coronary heart disease, and obstructive sleep apnea. Also Read: Fat-busting drug Mounjaro launched in India. Here's how much it will cost Promise of simplified treatment KwikPen, or Mounjaro, is a multi-dose, prescription-based, single-patient-use pre-filled pen designed for once-weekly administration, the company said. It also added that the full range of doses for Mounjaro—2.5 mg to 15 mg—will be available in India soon, supporting personalised treatment as recommended by treating physicians. Earlier, the vial format of the drug was launched in only two dosage strengths—2.5 mg and 5 mg—in the country. The latest announcement came after Wegovy, which has semaglutide as its API, got a strategic launch in India as an innovative, easy-to-use pre-filled pen called FlexTouch devices. It was aimed at stealing the thunder Mounjaro had by reaching Indian patients first. A less potent version of semaglutide, in the form of an oral pill-under the brand name of Rybelsus, has been available in India since 2022 for the treatment of diabetes. The Wegovy pre-filled pen has been launched in five dosing strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. While the monthly cost of the first three dosages is Rs 17,345, the higher doses will cost Rs 24,280 and Rs 26,050, respectively. Mounjaro, in the vial format, was launched at a cost of Rs 14,000 (for 2.5 mg) and Rs 17,500. Eli Lilly, however, has yet to decide the price of the Mounjaro KwikPen for all five dosages. Meanwhile, experts ThePrint spoke to said pre-filled pens will simplify treatment, making these powerful anti-obesity and diabetes medications more convenient for patients. 'With simplified administration, adherence improves, helping more individuals achieve better weight and metabolic health outcomes,' explained Mumbai-based diabetologist Dr Rajiv Kovil. Senior diabetologist and researcher Dr V. Mohan also said this could make a profound impact on the lives of lakhs of people in India. Mounjaro vs Wegovy—which is more effective Both tirzepatide and semaglutide, the prescription-only drugs, mimic the effects of natural gut hormones that work by lowering caloric intake, primarily by influencing appetite control mechanisms. Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, while semaglutide functions as a mono GLP-1 receptor agonist. Both GIP and GLP-1 are natural incretin hormones, that stimulate a decrease in blood glucose levels, found in brain regions that regulate appetite. In May this year, Lilly said in a statement that a head-to-head clinical trial comparing tirzepatide and semaglutide in their maximum tolerable doses showed the former to be significantly more effective than the latter in reducing both weight and waist circumference after 72 weeks of treatment. According to the US-based pharma giant, participants administered tirzepatide saw an average weight reduction of 20.2 percent, while those on semaglutide experienced a 13.7 percent loss—indicating a 47 percent greater relative weight loss for the former, based on the treatment regimen estimated at 72 weeks. But one advantage that semaglutide has in the higher dose strength is its ability to also treat several other metabolic conditions, such as cardiovascular diseases and kidney disorders. While Mounjaro is better than Wegovy in percentage of weight loss, there is stronger evidence in the case of Wegovy for reducing cardiovascular conditions in obese people without diabetes and also for treating kidney and diabetes, experts said. During the launch of Wegovy on 24 June, Novo Nordisk underlined that the drug is the only medication approved in India for treating major adverse cardiovascular events (MACE), along with obesity. Diabetologist Kovil said, 'If there is an obese patient who does not have other major underlying issues yet, I will be more inclined towards prescribing Mounjaro.' He added that, in patients with comorbidities such as diabetes, liver or kidney disorder or cardiovascular condition, Wegovy could be a better choice as it reduces mortality and improves longevity. In response to queries by ThePrint, Eli Lilly said that Mounjaro offers a novel approach to metabolic health management, giving treating physicians an innovative option for treating both diabetes and obesity. 'Ultimately, it is up to physicians to determine the most appropriate treatment based on individual patient needs and clinical judgment,' said the drugmaker. According to Dr Ambrish Mithal, chairman and head, endocrinology and diabetes with Max Healthcare, anti-obesity drugs can be indicated for people with a BMI (Body Mass Index) of 30 and above in the absence of other comorbidities. However, in people with other pre-existing conditions, either of the drugs can be initiated at a BMI of 27 and above, in conjunction with diet, lifestyle changes and under expert supervision, he said. Experts also warn about the possible side effects of GLP-1 agonist drugs amid concerns around misuse of these drugs in India, given the regulatory loopholes which allow patients to access most prescription drugs over the counter. Large clinical trials and post-marketing evidence following use of these medicines have shown that while nausea, bloating, vomiting and diarrhoea are comparatively mild side effects of these medications. In rare cases, they can also cause stomach paralysis, a disorder that affects the normal movement of the stomach muscles. In a response to queries by ThePrint, Eli Lilly emphasised that Mounjaro is a prescription-only drug and should be taken strictly under a doctor's supervision. 'Tirzepatide is not approved for, and should not be used for, cosmetic weight loss or by individuals under 18. Lilly neither promotes nor encourages the unapproved use of tirzepatide by anyone,' the company said. (Edited by Sanya Mathur) Also Read: Mounjaro will shrink India's appetite for packaged food, gyms, weight loss supplements
&w=3840&q=100)
Business Standard
10 hours ago
- Health
- Business Standard
India approves Eli Lilly's Mounjaro pen for diabetes, weight control
US pharma major Eli Lilly has now received approval from India's top drug regulator, the Central Drugs Standard Control Organisation (CDSCO), for its Mounjaro (tirzepatide) KwikPen format. Earlier in March, the company had launched Mounjaro in injectable vial form in 2.5 mg and 5 mg strengths. What is Mounjaro KwikPen and how does it work? According to Eli Lilly, the Mounjaro KwikPen is a multi-dose, single-patient-use, prefilled pen designed for once-weekly injections. It offers a more convenient way for people with type 2 diabetes and obesity to take their medication. Mounjaro is the first and only drug that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors—two hormones that help regulate blood sugar and appetite. In simple terms, Mounjaro helps: Improve insulin production Lower blood sugar levels Reduce body weight Control appetite All six dosage options of Mounjaro (2.5 mg to 15 mg) will soon be available in India. How does Mounjaro support weight management? The drug acts on hunger-regulating centres in the brain and slows stomach emptying, helping users feel full for longer. Clinical data show it improves fat metabolism and reduces body fat, contributing to weight loss. Who is eligible to use the Mounjaro KwikPen? The KwikPen is approved as an adjunct treatment with diet and exercise for: Adults with type 2 diabetes Adults with obesity (BMI ≥ 30) Overweight adults (BMI ≥ 27) with at least one weight-related condition such as high blood pressure or cholesterol When will Mounjaro KwikPen be available in India? While CDSCO has granted marketing authorisation, Lilly has not disclosed a launch date or pricing. The company has said this information will be announced soon. Mounjaro in vial form is priced at ₹3,500 (2.5 mg) and ₹4,375 (5 mg). Expert voices caution on long-term efficacy Speaking to Business Standard, Dr Ashish Gautam, Senior Director, Robotic and Laparoscopic Surgery at Max Super Speciality Hospital, said: 'The response towards anti-obesity medication in India has been positive, but the long-term benefits are yet to be established. While the medicines show good results during usage, weight tends to come back once medication is stopped.' He added that while drugs like Mounjaro are effective during use, bariatric surgery remains a more reliable long-term option for obesity. Sales surge and new competition from Wegovy According to PharmaTrac, Mounjaro has sold over 81,570 units in India as of May, with a 60 per cent rise in sales between April and May. On Tuesday, Danish drugmaker Novo Nordisk launched its blockbuster weight-loss drug Wegovy in India. It is expected to hit pharmacies by the end of the month, according to Novo Nordisk India MD Vikrant Shrotriya. India's obesity and diabetes burden continues to grow The National Family Health Survey (NFHS)-5 (2019–21) found that 24 per cent of women and 23 per cent of men aged 15–49 were overweight or obese, a sharp rise from 2015–16. The International Diabetes Federation projects that the number of adults with diabetes in India will grow from 74.2 million in 2021 to over 124 million by 2045.
Time of India
12 hours ago
- Health
- Time of India
Eli Lilly to launch Mounjaro KwikPen for type 2 diabetes in India
US pharmaceutical major Eli Lilly on Thursday announced plans to launch its blockbuster diabetes drug Mounjaro in KwikPen , a single patient use prefilled pen designed for once weekly administration in the Indian market, offering a convenient treatment option for adults with type 2 diabetes . The announcement comes two days after its rival Danish drugmarker Novo Nordisk , launched its weight loss drug Wegovy as a once a week injection in India. The company said that they have received approval from the drug regulatory authority however did not comment on the launch timeline. Lilly said each pen delivers four fixed doses of 0.6 mL and has been approved in six dose strengths including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, the company said in a statement. 'The approval of Mounjaro KwikPen marks a step forward in the care of people living with type 2 diabetes and obesity, offering a convenient way for patients to take their medication,' said Winselow Tucker, President and General Manager, Lilly India. Live Events 'With this approval, all six dosage options for Mounjaro ( tirzepatide ) will soon be available in India, supporting a more personalised approach to treatment and allowing healthcare professionals to tailor care based on individual patient needs and clinical goals.' Mounjaro (tirzepatide) is the first and only dual GIP (glucose- dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and chronic weight management in adults with obesity or overweight, with one weight-related comorbidity. Earlier in March the company had launched Mounjaro in 2.5 mg vial and 5 mg vial at Rs 3500 and Rs 4375 diabetes and nearly half of these adult patients are inadequately treated with suboptimal glycemic control. Mounjaro reduces body weight, and decreases fat mass by regulating appetite. Moreover, Mounjaro has been demonstrated to regulate lipid utilization. Over the past five years, the Indian market for weight loss drugs has grown over 30% CAGR to close to 550 crore, industry sources told ET. India has about 101 million people living with diabetes and nearly half of these in the adult patients category are being inadequately treated with suboptimal glycemic control. As of 2023, adult obesity prevalence in India stood at around 6.5%, affecting nearly 100 million people.
New Indian Express
12 hours ago
- Health
- New Indian Express
India approves Eli Lilly's Mounjaro KwikPen for diabetes and obesity, offering a novel dual-action therapy
NEW DELHI: India's drug regulator has approved Eli Lilly and Company's diabetes and obesity drug Mounjaro in a KwikPen presentation, the pharmaceutical giant announced on Thursday. The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorisation for Mounjaro (tirzepatide) in the KwikPen format in India. According to the company, it is a multi-dose, prescription-based, single-patient-use prefilled pen designed for once-weekly administration. Each pen delivers four fixed doses of 0.6 mL and has been approved in six dosage strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. 'Mounjaro (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with one weight-related comorbidity,' the company said in a statement. The announcement comes just days after Novo Nordisk revealed the launch of its weight-loss product Wegovy, which is yet to be made available in India. 'The approval of Mounjaro KwikPen marks a step forward in the care of people living with type 2 diabetes and obesity, offering a convenient way for patients to take their medication,' said Winselow Tucker, President and General Manager, Lilly India.
